{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:32:37Z","timestamp":1775655157566,"version":"3.50.1"},"reference-count":21,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myeloid neoplasms (MNs) constitute a diverse group of haematological malignancies that includes myelodysplastic neoplasms (MDS), myeloproliferative neoplasms (MPN), MDS\/MPN overlap syndrome, and acute myeloid leukaemia (AML) [...]<\/jats:p>","DOI":"10.3390\/ijms25042056","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T03:36:17Z","timestamp":1707363377000},"page":"2056","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Special Issue \u201cAdvances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms\u201d"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-7852","authenticated-orcid":false,"given":"Chung Hoow","family":"Kok","sequence":"first","affiliation":[{"name":"Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide 5000, Australia"},{"name":"Adelaide Medical School, University of Adelaide, Adelaide 5000, Australia"},{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide 5000, Australia"},{"name":"Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide 5000, Australia"},{"name":"Adelaide Medical School, University of Adelaide, Adelaide 5000, Australia"},{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide 5000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devendra K.","family":"Hiwase","sequence":"additional","affiliation":[{"name":"Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide 5000, Australia"},{"name":"Adelaide Medical School, University of Adelaide, Adelaide 5000, Australia"},{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide 5000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: When genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/s41375-022-01686-y","article-title":"A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure","volume":"36","author":"Kutyna","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic Germline Variants in 10,389 Adult Cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1038\/s41375-021-01246-w","article-title":"Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer","volume":"35","author":"Singhal","year":"2021","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41375-018-0051-y","article-title":"Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: Are we there yet?","volume":"32","author":"Tawana","year":"2018","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/bloodadvances.2022007211","article-title":"Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations","volume":"6","author":"Drazer","year":"2022","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1182\/bloodadvances.2023010045","article-title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41","volume":"7","author":"Homan","year":"2023","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","article-title":"RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41409-023-01970-0","article-title":"Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: A multicenter study","volume":"58","author":"Baranwal","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11899-022-00676-2","article-title":"Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms","volume":"17","author":"Baranwal","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","article-title":"Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies","volume":"7","author":"Saygin","year":"2023","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/2056\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:56Z","timestamp":1760104616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/2056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25042056"],"URL":"https:\/\/doi.org\/10.3390\/ijms25042056","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}